
    
      This is a single-center study to evaluate the clinical outcomes of Lotemax 0.5% for the
      treatment of Ocular inflammation associated with cataract surgery. Subjects will be screened
      from one to 21 days prior to initiation of dosing with the test article. Subjects who sign
      the informed consent document and meet all inclusion/exclusion criteria will be eligible to
      participate in this study. Subjects will instill one drop of Lotemax into the study
      (operative) eye QID for a maximum of 22 days. Dosing with test article will begin the day of
      surgery and for 21 days after surgery. Subjects will be seen for evaluation on Days 1, 7±1,
      and 21 ± 2 following surgery. Subjects will be seen for a follow-up visit on Day 42 ± 3
      following surgery, about 21 days after their last dose of test article.

      In addition to the test article regimen, subjects will receive Vigamox TID 3 days prior to
      surgery. Patients will receive one drop of Timoptic XE 0.5%, Zymaxid on the day of surgery.
      Postoperatively, patients will receive Vigamox TID for ten days and Bromday QD for 3 weeks.
    
  